Vimarsana
Biggest News Aggregation in the World

Page 2 - Randomized Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Randomized Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Randomized Evaluation Today - Breaking & Trending Today

Is Geography Our Destiny in the Next Pandemic? - Vimarsana News

Is Geography Our Destiny in the Next Pandemic?

Politics and lack of trust in public health threaten future crisis responses

New school-based group counseling programs can significantly reduce PTSD among girls - Vimarsana News

New school-based group counseling programs can significantly reduce PTSD among girls

The University of Chicago Education Lab today released a new study that found school-based group counseling programs can significantly reduce PTSD, anxiety, and depression among Black and Latina girls.

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial | Critical Care Medicine | JAMA - Vimarsana News

Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial | Critical Care Medicine | JAMA

This open label clinical trial compares the effects of dexamethasone vs usual care on the number of days alive and free of mechanical ventilation at day 28 amon

Cytokinetics Presents New Data in Patients With - Vimarsana News

Cytokinetics Presents New Data in Patients With

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and...

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress - Vimarsana News

Cytokinetics Presents New Data in Patients With Non-Obstructive HCM From Cohort 4 of REDWOOD-HCM in Late-Breaking Clinical Trial Session at The European Society of Cardiology Heart Failure 2023 Congress

Treatment of Aficamten was Well-Tolerated and Associated with Statistically Significant Improvements in KCCQ, Angina Frequency, NYHA Class, NTpro-BNP and High-Sensitivity Troponin I Phase 3 Clinical... | May 20, 2023